Briefing
Serial circulating tumour DNA monitoring in first-line advanced NSCLC (COPE): a randomized, two-arm non-comparative phase II trial
COPE randomized 176 patients with previously untreated advanced NSCLC 2:1 to serial plasma profiling with weekly molecular tumor board review (n=117) or standard management (n=59). Eighteen-month overall survival was 53.8% in the monitoring arm and 65.7% in the standard-management arm; no between-arm comparison was planned, and the authors concluded that clinical benefit was not demonstrated. In 90 patients with paired early on-treatment samples, ctDNA clearance was associated with longer progression-free survival (22.9 vs 5.4 months) and overall survival (not reached vs 17.1 months) than persistent detection.
- Design: Evidence level 2
- Assay: Not named in the abstract
Clinical Cancer ResearchPubMed 42905748DOI 10.1158/1078-0432.CCR-26-2812